Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17895646 | 0.81 | GAA (0.67) | GAAMEN1KMT2AALDH1A1RAB9A | |
| SCHEMBL8142798 | 0.79 | CDK2 (0.42) | GAAMEN1KMT2AALDH1A1RAB9A | |
| SCHEMBL26546523 | 0.78 | CDK2 (0.38) | GAAMEN1KMT2AALDH1A1RAB9A | |
| SCHEMBL16908932 | 0.77 | GAA (0.60) | GAAMEN1KMT2AALDH1A1RAB9A | |
| SCHEMBL28979284 | 0.76 | GAA (0.52) | GAAMEN1KMT2AALDH1A1RAB9A | |
| SCHEMBL2616832 | 0.75 | GAA (0.58) | GAAMEN1KMT2AALDH1A1RAB9A | |
| SCHEMBL8919365 | 0.74 | GAA (0.58) | GAAMEN1KMT2AALDH1A1RAB9A | |
| SCHEMBL14184594 | 0.74 | MEN1 (0.69) | GAAMEN1KMT2AALDH1A1RAB9A | |
| SCHEMBL299269 | 0.74 | GAA (0.56) | GAAMEN1KMT2AALDH1A1RAB9A | |
| SCHEMBL9750695 | 0.73 | P2RY1 (0.48) | MEN1KMT2AALDH1A1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150080569-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| US-20150080569-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| US-8809266-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8809266-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-20130274439-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2013-10-17 | — | — | US | disclosed |
| US-20130274439-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2013-10-17 | — | — | US | disclosed |
| US-8420597-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2013-04-16 | — | — | US | disclosed |
| US-8420597-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2013-04-16 | — | — | US | disclosed |
| US-20130053577-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-02-28 | — | — | US | disclosed |
| US-20130053577-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-02-28 | — | — | US | disclosed |
| US-8283442-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2012-10-09 | — | — | US | disclosed |
| US-20120190866-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120190866-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-07-26 | — | — | US | disclosed |
| US-8178491-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178491-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20110306541-A1 | METHODS FOR TREATING HCV | GILEAD SCIENCES, INC. (US) | 2011-12-15 | — | — | US | disclosed |
| US-20110306541-A1 | METHODS FOR TREATING HCV | GILEAD SCIENCES, INC. (US) | 2011-12-15 | — | — | US | disclosed |
| US-20090257978-A1 | Antiviral coumpounds | GILEAD SCIENCES, INC. (US) | 2009-10-15 | — | — | US | disclosed |
| US-20090257978-A1 | Antiviral coumpounds | GILEAD SCIENCES, INC. (US) | 2009-10-15 | — | — | US | disclosed |
| WO-2009005676-A2 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306541-A1 | METHODS FOR TREATING HCV | HAVCR2, HCCS, LIPC | GAA 758/4885MEN1 4840/4885KMT2A 4079/4885 |
| US-20130274439-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | GAA 151/4885MEN1 4292/4885KMT2A 3803/4885 |
| US-20090257978-A1 | Antiviral coumpounds | MAVS, ZC3HAV1, EIF2AK2 | GAA 135/4885MEN1 4308/4885KMT2A 4346/4885 |
| US-20130053577-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | GAA 151/4885MEN1 4292/4885KMT2A 3803/4885 |
| US-20120190866-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | GAA 151/4885MEN1 4292/4885KMT2A 3803/4885 |
| US-20150080569-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | GAA 151/4885MEN1 4292/4885KMT2A 3803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.